Since its inception in 2010, SIMI has been producing productive discussions resulting in multiple successful partnerships and collaborations. As a brief synopsis of our track record, in 2018, SIMI originated and led the $667.6M deal between Roivant Science and iNtRON Biotechnology for a novel MRSA targeting antibacterial molecule and all of iNtRON’s remaining endolysin pipelines at right-of-first negotiation and pre-determined terms for licensing. In 2017, SIMI negotiated and consulted HanAll Biopharma’s exclusive license of their novel immunology product to Harbour BioMed and Roivant Science for $81M and over $500M respectively. In 2012, SIMI led the $139M deal between AstraZeneca and Legochem for their antibiotic program, which received the honor of being shortlisted for the 2013 SCRIP Award for Best Partnership Alliance.
Licensing-Out Agreement
Licensing-Out Agreement
Licensing-Out Agreement
Spin-off / Joint Venture Agreement
Licensing-Out Agreement
Collaboration & Option Licensing Agreement